News and Announcements
Rakon’s Investment in IoT Start Up Thinxtra Instrumental in Driving Their Growth
- Published June 23, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Thinxtra, founded in 2015, holds licences for Australia, New Zealand and Hong Kong to proprietary low powered wide area network (LPWAN) wireless technology for IoT from French company Sigfox and is well advanced in rolling out networks in Australia and New Zealand.
KEY TAKEAWAYS:
- Rakon has made two investments in Thinxtra and holds 42 percent of its equity.
- Its initial investment of $A0.8m in December 2015 for 11 percent of the company was topped up with a further $4.2m in April 2016.
- Rakon chairman Bryan Mogridge also chairs Thinxtra and has personally invested $550,000 in the company.
- Thinxtra was in a unique position to lead the IoT revolution within its territory of Australia, New Zealand and Hong Kong.
Thinxtra CEO, Loic Barancourt said: “Our relationship with Rakon has enabled Thinxtra to be a strong New Zealand influencer and is a strong reference for Thinxtra when talking to large customers or institutional investors. Additionally, Bryan and Brent bring solid technical, commercial and financial experience and governance to the Board.”
“Thinxtra, at this early stage, has 1.5 million committed connections from existing customers with a gross revenue committed of $A18 million over the next eight years, and it has over 50 million potential connections in its current pipeline.”
He added: “Thinxtra is in the process of a Series B round of fund raising for $A15 million, with 33 percent of that committed, and the remainder in advanced stages of discussion and due diligence with interested parties. This round of capital raising is anticipated to be sufficient to complete Thinxtra’s network build within the three countries it will cover. It should also be sufficient to enable Thinxtra to develop its active customer base sufficiently, for the cash flow to sustain the business’s ongoing activities.”
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
